Immunoregulatory Effect of Anti-thymocyte Globulin Monotherapy on Peripheral Lymphoid Tissues of Non-obese Diabetic Mice

Vargova, L.; Zacharovová, K.; Dovolilová, Eva; Vojtová, L; Saudek, F

doi:10.1016/j.transproceed.2011.09.057

Search citation statements

Order By: Relevance

Paper Sections

Select...

Anti-thymocyte Globulin Therapy1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In NOD mice, treatment with ATG at a preclinical T1D stage prevents diabetes onset (Simon et al 2008). However, only a modest effect is seen in newly diabetic NOD mice; *30 % of animals receiving ATG undergo remission (Parker et al 2009;Vargova et al 2011). Interestingly, the effects of ATG are dependent on the activation status and subset of Ab-bound T cells.…”

Section: Anti-thymocyte Globulin Therapymentioning

confidence: 99%

Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes

Morillon

Martin

Gojanovich

et al. 2015

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Type 1 diabetes (T1D) is an autoimmune disease in which the insulin-producing b cells are selectively destroyed. b cell-specific T cells are considered to be the major mediators of pathology. Accordingly, most immunotherapies tested in the clinic to date have focused on reestablishing self-tolerance within the T cell compartment. Monoclonal antibodies (Ab) targeting a variety of lymphocyte surface proteins have demonstrated benefits in preclinical and clinical settings. Indeed, the use of Ab to target T cells directly or indirectly has proven to be an effective strategy to rapidly suppress b cell autoimmunity and establish tissue-specific, long-term tolerance in rodent T1D models. In this review, we describe a number of these Ab-based immunotherapies, discuss associated immune regulatory mechanisms, and highlight results obtained in T1D clinical trials.

show abstract

Section: Anti-thymocyte Globulin Therapymentioning

confidence: 99%